In summary, while preclinical studies have shown promising results, with GLP-1-RA inhibiting cancer cell proliferation and showing synergistic effects when combined with Metformin or RT, clinical data on its impact on PCa outcomes are currently insufficient. The gene discussed is GLP1R; the disease is cancer.